Conventional drugs often face challenges associated with poor harmacokinetics, low aqueous solubility, and rapid clearance from the circulation. These issues contribute to their limited effectiveness and necessitate generally high therapeutic doses. The utilization of nanocarriers in drug delivery can mitigate rapid degradation, resulting in increased drug half-life. Additionally, it can enhance drug solubility and stability, facilitate improved distribution and targeting, enable sustained release, and diminish drug resistance by delivering multiple therapeutic agents simultaneously.
Moreover, nanotechnology allows for the integration of therapeutics with biomedical imaging agents and other treatment modalities, addressing the challenges of disease diagnosis and therapy. This integrated approach, known as "theranostics," aims to provide a more patient-specific strategy by observing the distribution of contrast agents linked to therapeutics.
In this presentation, I will provide an overview of magnetic resonance experiment results dedicated to the search for theranostic compounds with optimal characteristics for the improvement of diagnostic and therapy.
